Thermo Fisher Scientific (TMO) to Release Quarterly Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO) is expected to be announcing its Q1 2025 earnings results before the market opens on Wednesday, April 23rd. Analysts expect Thermo Fisher Scientific to post earnings of $5.11 per share and revenue of $10.23 billion for the quarter. Thermo Fisher Scientific has set its FY 2025 guidance at 23.100-23.500 EPS.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Trading Down 1.2 %

NYSE:TMO opened at $422.43 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $159.46 billion, a PE ratio of 25.56, a PEG ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific has a one year low of $409.85 and a one year high of $627.88. The firm has a 50-day moving average of $495.35 and a 200-day moving average of $531.39.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific’s payout ratio is 10.41%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares in the company, valued at $59,506,950.58. The trade was a 7.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $13,106,062 over the last 90 days. 0.34% of the stock is owned by insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

A hedge fund recently raised its stake in Thermo Fisher Scientific stock. Brighton Jones LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.9% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 4,409 shares of the medical research company’s stock after acquiring an additional 988 shares during the period. Brighton Jones LLC’s holdings in Thermo Fisher Scientific were worth $2,293,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on TMO. Scotiabank increased their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a report on Monday, February 3rd. Morgan Stanley raised their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $642.67.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.